Viewray Inc Revenue Growth Rates (VRAY), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Viewray Inc   (NASDAQ: VRAY)
 

VRAY's Revenue Growth by Quarter and Year

Viewray Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

VRAY Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 22.53
FY 22.53

VRAYs Annual Revenue
Viewray Inc 's Revenue in the fiscal year 2022 $ 102.21 millions
Viewray Inc 's Revenue in the fiscal year 2021 $ 70.12 millions
Viewray Inc 's Revenue in the fiscal year 2020 $ 57.02 millions
Viewray Inc 's Revenue in the fiscal year 2019 $ 87.78 millions
Viewray Inc 's Revenue in the fiscal year 2018 $ 80.96 millions




VRAY Revenue first quarter 2023 Y/Y Growth Comment
Viewray Inc reported Revenue increase of 19.35% year on year in the first quarter 2023, to $ 22.53 millions, this is lower than Viewray Inc 's recent average Revenue surge of 221.38%.

Looking into first quarter 2023 results within Medical Equipment & Supplies industry 34 other companies have achieved higher Revenue growth. While Viewray Inc ' s Revenue growth of 19.35% ranks overall at the positon no. 754 in the first quarter 2023.


VRAY Revenue ( Y/Y Growth %) 2023
 2022 2021 2020
4th Quarter December - 70.13 % 10.46 % 12.08 %
3rd Quarter September - 38.11 % 90.09 % -51.63 %
2nd Quarter June - 47.37 % 5.7 % -52.87 %
1st Quarter March 19.35 % 21.57 % 8.98 % -29.73 %
FY   - 45.74 % 22.99 % -

Financial Statements
Viewray Inc 's first quarter 2023 Revenue $ 22.53 millions VRAY's Income Statement
Viewray Inc 's first quarter 2022 Revenue $ 18.88 millions Quarterly VRAY's Income Statement


VRAY Revenue (Quarter on Quarter Growth %)

 2023
 2022 2021 2020
4th Quarter December - 30.96 % 6.31 % 82.95 %
3rd Quarter September - 19.59 % 27.61 % -29.04 %
2nd Quarter June - 17.32 % -3.22 % -0.21 %
1st Quarter March -35.04 % -7.41 % -15.87 % -13.48 %
FY (Year on Year)   - 45.74 % 22.99 % -


Back to VRAY Growth rate Comparisons >> Back to VRAY Growth rate Comparisons >>


Revenue first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #35
Healthcare Sector #157
Overall #754

Revenue Y/Y Growth Statistics
High Average Low
3699.87 % 221.38 % -40.17 %
(Sep 30 2017)   (Sep 30 2020)
Revenue first quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #35
Healthcare Sector #157
Overall #754
Revenue Y/Y Growth Statistics
High Average Low
3699.87 % 221.38 % -40.17 %
(Sep 30 2017)   (Sep 30 2020)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Viewray Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
4416.81 % 217.97 % -94.52 %
(Dec 31 2016)  


VRAY's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2023 Viewray Inc disclosed fall in Revenue from the fourth quarter by -35.04% to $ 22.53 millions, from $ 34.69 millions achived in the previous reporting period.

But that's not important problem, as Viewray Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 197 other companies have achieved higher Revenue quarter on quarter growth. While Viewray Inc 's Revenue growth quarter on quarter, overall rank is 4209.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #198
Healthcare Sector #663
Overall #4209
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #198
Healthcare Sector #663
Overall #4209
Revenue Q/Q Growth Statistics
High Average Low
4416.81 % 217.97 % -94.52 %
(Dec 31 2016)  


VRAY's I. Quarter Q/Q Revenue Comment
In the I. Quarter 2023 Viewray Inc disclosed fall in Revenue from the fourth quarter by -35.04% to $ 22.53 millions, from $ 34.69 millions achived in the previous reporting period.

But that's not important problem, as Viewray Inc 's Revenue generally seem to plunge in this quarter.

Within Medical Equipment & Supplies industry 197 other companies have achieved higher Revenue quarter on quarter growth. While Viewray Inc 's Revenue growth quarter on quarter, overall rank is 4209.


Viewray Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2023)		 12 Months Ending
(Dec 31 2022)		 12 Months Ending
(Sep 30 2022)		 12 Months Ending
(Jun 30 2022)		 12 Months Ending
(Mar 31 2022)
Cumulative Revenue 12 Months Ending $ 105.86 $ 102.21 $ 87.90 $ 80.59 $ 73.47
Y / Y Revenue Growth (TTM) 44.09 % 45.76 % 28.91 % 36.37 % 26.04 %
Year on Year Revenue Growth Overall Ranking # 591 # 2120 # 431 # 0 # 2211
Seqeuential Revenue Change (TTM) 3.58 % 16.27 % 9.07 % 9.69 % 4.78 %
Seq. Revenue Growth (TTM) Overall Ranking # 754 # 746 # 164 # 2977 # 2307


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2023 period, Viewray Inc 's cumulative twelve months Revenue were $ 106 millions, company would post below average annual Revenue growth of 4.78% year on year, if the fiscal year would end at Mar 31 2023.
A slow-down in the Viewray Inc 's Revenue growth from the 34.69% growth in Dec 31 2022.

In the Healthcare sector 129 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 591, from total ranking in previous quarter at 2120.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 35
Healthcare Sector # 130
Overall # 591

Revenue TTM Y/Y Growth Statistics
High Average Low
3699.87 %
 221.38 %
-40.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 35
Sector # 157
S&P 500 # 754
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Mar 31 2023 period, Viewray Inc 's cumulative twelve months Revenue were $ 106 millions, company would post below average annual Revenue growth of -40.17% year on year, if the fiscal year would end at Mar 31 2023.
A slow-down in the Viewray Inc 's Revenue growth from the 34.69% growth in Dec 31 2022.

In the Healthcare sector 129 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 591, from total ranking in previous quarter at 2120.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 35
Healthcare Sector # 130
Overall # 591

Revenue TTM Y/Y Growth Statistics
High Average Low
3699.87 %
221.38 %
-40.17 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 35
Sector # 157
S&P 500 # 754




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
VRAY's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Mar 31 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2023
Schrodinger Inc 33.12%$ 33.124 millions
Caribou Biosciences Inc 31.46%$ 31.456 millions
Volitionrx Limited31.17%$ 31.168 millions
Medpace Holdings Inc 31.16%$ 31.161 millions
Sonoma Pharmaceuticals Inc 31.16%$ 31.158 millions
Immunogen inc 30.97%$ 30.965 millions
Ensysce Biosciences Inc 30.93%$ 30.930 millions
Bionano Genomics Inc 30.18%$ 30.179 millions
Semler Scientific inc 29.89%$ 29.894 millions
Pulmatrix Inc 29.22%$ 29.224 millions
Esperion Therapeutics Inc 29.16%$ 29.162 millions
Janux Therapeutics Inc 28.89%$ 28.886 millions
Rockwell Medical inc 28.82%$ 28.822 millions
Eargo Inc 28.74%$ 28.738 millions
Tvardi Therapeutics Inc 28.71%$ 28.706 millions
Liquidia Corporation28.67%$ 28.666 millions
Biotricity Inc 27.63%$ 27.630 millions
Neuropace Inc 27.24%$ 27.238 millions
Ethema Health Corporation 27.04%$ 27.043 millions
Bicycle Therapeutics Plc26.84%$ 26.839 millions
Urogen Pharma Ltd 26.75%$ 26.747 millions
Akoya Biosciences Inc 26.73%$ 26.731 millions
Sight Sciences Inc 26.50%$ 26.497 millions
Caremax Inc 26.34%$ 26.339 millions
Heron Therapeutics Inc 26.25%$ 26.252 millions
Dmk Pharmaceuticals Corporation25.85%$ 25.854 millions
Paragon 28 inc 25.78%$ 25.779 millions
Ultragenyx Pharmaceutical Inc 25.72%$ 25.722 millions
Iradimed Corporation25.70%$ 25.704 millions
Paratek Pharmaceuticals Inc 25.64%$ 25.643 millions


About Viewray Inc Revenue Growth Rates (VRAY), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Viewray Inc (CIK 1597313).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001628280-23-017657
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Viewray Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.